Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is projected to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.08). On average, analysts expect Zentalis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $4.09 on Wednesday. Zentalis Pharmaceuticals has a one year low of $1.13 and a one year high of $6.95. The stock has a fifty day moving average price of $3.22 and a 200 day moving average price of $2.36. The stock has a market cap of $291.17 million, a P/E ratio of -2.15 and a beta of 1.99.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ZNTL shares. Guggenheim raised their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Tuesday, April 7th. Finally, Wells Fargo & Company started coverage on Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $5.83.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93. Following the sale, the insider directly owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 43,521 shares of company stock worth $105,539 over the last quarter. 1.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ZNTL. Invesco Ltd. increased its holdings in Zentalis Pharmaceuticals by 8.6% during the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock valued at $255,000 after purchasing an additional 14,961 shares in the last quarter. Vanguard Group Inc. boosted its stake in Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock worth $4,386,000 after purchasing an additional 19,768 shares in the last quarter. Quarry LP grew its holdings in shares of Zentalis Pharmaceuticals by 21.4% during the fourth quarter. Quarry LP now owns 132,000 shares of the company’s stock worth $178,000 after purchasing an additional 23,250 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Zentalis Pharmaceuticals by 76.4% during the third quarter. Qube Research & Technologies Ltd now owns 56,639 shares of the company’s stock worth $86,000 after purchasing an additional 24,526 shares during the last quarter. Finally, Voleon Capital Management LP acquired a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at $41,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.